CEDAR KNOLLS, N.J.,
Sept. 10, 2019 /PRNewswire/ -- MYOS
RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), an
advanced nutrition company and the owner of
Fortetropin®, a proprietary bioactive composition made
from fertilized egg yolk that helps build lean muscle, has entered
into a research agreement with the Department of Kinesiology at
McMaster University in Hamilton, Canada. The study will examine the
impact of Fortetropin on reducing muscle disuse atrophy in young
men. Muscle atrophy due to disuse commonly occurs in response to
immobilization such as the atrophy of the thigh muscles following a
period of casting for fracture or following surgery such as knee
replacement.
Fortetropin is a natural food product made from fertilized hen
egg yolks that has been shown to minimize disuse atrophy in the
thigh muscles of dogs that had undergone leg ligament repair
surgery. The Principal Investigator for this clinical study
will be Stuart M. Phillips, PhD,
Professor of Kinesiology, Canada Research Chair and Director,
Physical Activity Centre of Excellence (PACE) at McMaster University. Professor Phillips,
a key opinion leader in the field of muscle physiology and
sarcopenia with over 200 peer-reviewed publications to his credit,
will supervise an interdisciplinary team of scientists and
physicians.
Fortetropin has been clinically shown to increase muscle size,
lean body mass and strength as part of resistance training and to
increase the fractional synthetic rate (FSR) of muscle proteins in
older men and women (60-75 years of age).
In this randomized, double-blind, placebo-controlled clinical
study, 24 male subjects, will consume either Fortetropin or a
macronutrient-matched placebo for 6 weeks. After a 2-week
Fortetropin pre-treatment phase, subjects will wear a knee brace
for a period of 2 weeks in order to simulate immobilization-induced
muscle disuse atrophy. Following the immobilization phase,
subjects will remove the knee brace while continuing to consume
Fortetropin for an additional 2 weeks (recovery phase). In
order to assess the impact of Fortetropin on muscle atrophy, a
series of body composition measurements will be performed during
each phase of the study. In addition, muscle biopsy samples
will be collected during each phase, and in-depth biochemical
analyses will be performed.
"MYOS aims to become one of the leading medical nutrition
companies in the area of muscle recovery and rehabilitation.
Encouraged by promising results from multiple human and canine
clinical studies, we are delighted to work with the respected
research group of Professor Phillips at McMaster University. Completing this study is an
important part of our commercial strategy to increase our business
in a growing market with tremendous opportunity," commented
Joseph Mannello, CEO of MYOS.
Fortetropin has the potential to improve muscle health based on
multiple rigorous studies in both canines and humans. This
new study will build upon previous research which demonstrated that
Fortetropin minimizes muscle atrophy in dogs recovering from leg
ligament repair surgery. "We are excited to work with MYOS on
this human clinical trial. Very few nutrition products have
been studied to this degree," commented Dr. Phillips.
About MYOS RENS Technology Inc.
MYOS RENS
Technology Inc. (MYOS), "The Muscle Company®", is a
Cedar Knolls, NJ-based advanced
nutrition company that develops and markets products that improve
muscle health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size, lean body mass and strength in conjunction
with resistance training. For more information, please visit
www.myosrens.com.
Forward-Looking Statements
Any statements
in this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the success of our products, including
Qurr®, Yolked®, and MYOS Canine
Muscle Formula® , the success of our research
and development, the results of the clinical evaluation
of Fortetropin® and its effects,
including the clinical trial described above, the ability to enter
into new partnership opportunities and the success of our existing
partnerships, the ability to generate revenue and cash flow from
sales of our products, the ability to increase our revenue and
gross profit margins, the ability to achieve a sustainable,
profitable business, the effect of economic conditions, the ability
to protect our intellectual property rights, competition from other
providers and products, the continued listing of our securities on
the Nasdaq Stock Market, risks in product development, our ability
to raise capital to fund continuing operations, and other factors
discussed from time to time in our filings with the
Securities and Exchange Commission. We undertake no obligation to
update or revise any forward-looking statement for events or
circumstances after the date on which such statement is made except
as required by law.
These statements have not been evaluated by the
Food and Drug Administration. Our products are not intended to
diagnose, treat, cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Matthew Abenante, IRC, SVP
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-enters-into-research-agreement-with-mcmaster-university-to-study-impact-of-fortetropin-on-muscle-disuse-atrophy-in-young-men-300914540.html
SOURCE MYOS RENS Technology